Posted by Michael Wonder on 03 Nov 2021
Health Canada issues Notice of Compliance for Jardiance (empagliflozin) for the treatment of heart failure with reduced ejection fraction
2 November 2021 - This new indication is based on the EMPEROR-Reduced trial, which showed a significant 25% reduction in the combined relative risk versus placebo of cardiovascular death or hospitalisation for heart failure with reduced ejection fraction in adults with or without diabetes and an eGFR as low as 20mL/min/1.73 m2.
Boehringer Ingelheim and Eli Lilly are pleased to announce that Jardiance (empagliflozin) has been granted marketing authorization by Health Canada as a treatment for heart failure with reduced ejection fraction, as an adjunct to standard of care therapy, in adults with an eGFR as low as 20 mL/min/1.73 m.
